PBYI Stock Overview
A biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 0/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Puma Biotechnology, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.75 |
| 52 Week High | US$7.73 |
| 52 Week Low | US$2.23 |
| Beta | 1.08 |
| 1 Month Change | -8.33% |
| 3 Month Change | 7.84% |
| 1 Year Change | -33.25% |
| 3 Year Change | -20.52% |
| 5 Year Change | -68.24% |
| Change since IPO | -79.63% |
Recent News & Updates
Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward
Dec 16Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest
Nov 14
Recent updates
Puma Biotechnology: Continuing To Push Their Aurora Kinase Story Forward
Dec 16Puma Biotechnology's (NASDAQ:PBYI) Performance Is Even Better Than Its Earnings Suggest
Nov 14Is Puma Biotechnology (NASDAQ:PBYI) A Risky Investment?
Sep 07Lacklustre Performance Is Driving Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 26% Price Drop
Aug 15The Market Doesn't Like What It Sees From Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Earnings Yet As Shares Tumble 25%
Jun 07Here's Why We Think Puma Biotechnology (NASDAQ:PBYI) Might Deserve Your Attention Today
Jun 05We Like The Quality Of Puma Biotechnology's (NASDAQ:PBYI) Earnings
May 09Puma Biotechnology: A Story In Flux Heading Into Mid-2024
May 05Is There An Opportunity With Puma Biotechnology, Inc.'s (NASDAQ:PBYI) 46% Undervaluation?
Apr 10There's Reason For Concern Over Puma Biotechnology, Inc.'s (NASDAQ:PBYI) Massive 31% Price Jump
Mar 01Here's Why Puma Biotechnology (NASDAQ:PBYI) Has A Meaningful Debt Burden
Dec 27Puma Biotechnology (NASDAQ:PBYI) Has A Somewhat Strained Balance Sheet
Sep 08Puma Biotechnology, Inc. (NASDAQ:PBYI) Held Back By Insufficient Growth Even After Shares Climb 34%
Apr 17We Think Puma Biotechnology (NASDAQ:PBYI) Can Stay On Top Of Its Debt
Dec 14Puma Biotechnology, Takeda enter licensing agreement for cancer treatment alisertib
Sep 20Puma Biotechnology (NASDAQ:PBYI) Takes On Some Risk With Its Use Of Debt
Sep 05Shareholder Returns
| PBYI | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -4.5% | -3.6% | -2.4% |
| 1Y | -33.3% | -2.7% | 23.3% |
Return vs Industry: PBYI underperformed the US Biotechs industry which returned -2.7% over the past year.
Return vs Market: PBYI underperformed the US Market which returned 23.3% over the past year.
Price Volatility
| PBYI volatility | |
|---|---|
| PBYI Average Weekly Movement | 10.1% |
| Biotechs Industry Average Movement | 10.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: PBYI has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: PBYI's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 185 | Alan Auerbach | www.pumabiotechnology.com |
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer.
Puma Biotechnology, Inc. Fundamentals Summary
| PBYI fundamental statistics | |
|---|---|
| Market cap | US$134.99m |
| Earnings (TTM) | US$23.24m |
| Revenue (TTM) | US$243.57m |
5.8x
P/E Ratio0.6x
P/S RatioIs PBYI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PBYI income statement (TTM) | |
|---|---|
| Revenue | US$243.57m |
| Cost of Revenue | US$74.81m |
| Gross Profit | US$168.76m |
| Other Expenses | US$145.52m |
| Earnings | US$23.24m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.47 |
| Gross Margin | 69.29% |
| Net Profit Margin | 9.54% |
| Debt/Equity Ratio | 109.8% |
How did PBYI perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 02:07 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Puma Biotechnology, Inc. is covered by 17 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Huidong Wang | Barclays |
| Geoffrey Meacham | BofA Global Research |
| Alethia Young | Cantor Fitzgerald & Co. |